• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    A Look At Labcorp Holdings (LH) Valuation After Illumina Alliance Puts Precision Oncology In Focus

    Simply Wall St·03/27/2026 03:13:50
    Listen to the news

    Illumina alliance puts precision oncology in focus for Labcorp Holdings (LH)

    Labcorp Holdings (LH) is back in the spotlight after expanding its collaboration with Illumina to widen access to next generation sequencing based cancer testing and co develop new precision oncology diagnostics.

    See our latest analysis for Labcorp Holdings.

    For investors, the Illumina alliance arrives as Labcorp's 1-year total shareholder return of 17.09% and 3-year total shareholder return of 44.23% contrast with a recent 30-day share price return of 6.53% and a 90-day gain of 5.71%. This suggests momentum has cooled slightly following a stronger, longer run.

    If cancer diagnostics and genomics are on your radar, it could be a good time to broaden your search using our healthcare focused 36 healthcare AI stocks

    With Labcorp trading at $268.38 alongside an implied discount to both analyst targets and intrinsic estimates, the real question is whether recent Illumina news creates a fresh entry point or if markets already price in future growth.

    Most Popular Narrative: 12.8% Undervalued

    The most followed narrative pegs Labcorp's fair value at $307.71, above the last close at $268.38. This highlights the factors that may be driving that gap.

    The introduction of innovative tests in oncology, women's health, autoimmune disease, and neurology is anticipated to capture more test volume and outpace growth in the broader market, positively impacting revenue and earnings. The use of AI and technology innovations is enhancing operational efficiencies, improving margins through platforms like eClaim Assist and Labcorp Diagnostic Assistant.

    Read the complete narrative.

    Want to see what sits behind that higher fair value number? The narrative focuses on steadier revenue progress, firmer margins, and a richer earnings profile several years out.

    Result: Fair Value of $307.71 (UNDERVALUED)

    Have a read of the narrative in full and understand what's behind the forecasts.

    However, that upside story still hinges on tariffs, regulatory shifts, and Medicare pricing moves not exerting more pressure on Labcorp's revenue and margins than analysts expect.

    Find out about the key risks to this Labcorp Holdings narrative.

    Another View: P/E sends a tougher message

    The narrative and DCF style fair value of $307.71 points to upside, but the current P/E of 25.2x tells a tighter story. It sits above the US Healthcare industry at 21.5x and still below a fair ratio of 31x, so you are paying a premium, just not the fullest one the model suggests. Is that a margin of safety or simply less room for error?

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:LH P/E Ratio as at Mar 2026
    NYSE:LH P/E Ratio as at Mar 2026

    Next Steps

    With mixed signals on value and growth potential, do not wait for consensus to form. Check the numbers yourself and weigh up the 3 key rewards and 2 important warning signs

    Looking for more investment ideas?

    If Labcorp has caught your attention, do not stop here. Broaden your watchlist now so you are not late to other potential opportunities.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.